Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | THRA | P10827 | 6/20 | 0.68 |
| ▸ | THRB | P10828 | 6/20 | 0.68 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.67 |
| ▸ | RARB | P10826 | 3/20 | 0.63 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8591116 | 1.00 | TP53 (0.69) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL1437711 | 1.00 | TP53 (0.69) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL7861703 | 1.00 | TP53 (0.69) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL14644865 | 1.00 | TP53 (0.69) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL7861984 | 1.00 | TP53 (0.69) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL2356907 | 0.98 | TP53 (0.66) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL5055145 | 0.95 | L3MBTL1 (0.65) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL7371927 | 0.94 | RARB (0.68) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL11657851 | 0.90 | PLA2G4B (0.58) | TP53TSHRTHRATHRBPLA2G4B | |
| SCHEMBL5057170 | 0.88 | L3MBTL1 (0.70) | TP53TSHRTHRATHRBPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-2791112-B1 | CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES | CELGENE INT II SÀRL (CH) | 2020-09-23 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| WO-2006020951-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-0923529-B1 | SUBSTITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER AG (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-0923529-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5863915-A | ENZYME INHIBITORS FOR BONES AND JOINTS | BAYER CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1997043237-A1 | SUBSITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| US-5140046-A | Slow reacting substance of anaphylaxis antagonists | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-08-18 | — | — | US | disclosed |
| US-5116853-A | SRS-Antagonist, Antiallergens | MASE TOSHIYASU (JP) | 1992-05-26 | — | — | US | disclosed |
| US-4994479-A | Antagonists of SRS-A(slow reacting substance of anaphylaxis); antiallergens, antiischemic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0218728-A1 | PHENYLENE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
| WO-1986005779-A1 | PHENYLENE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | TP53 3798/4885TSHR 44/4885THRA 128/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | TP53 3798/4885TSHR 44/4885THRA 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.